Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 8/20 | 0.35 |
| ▸ | CTSL | P07711 | 5/20 | 0.33 |
| ▸ | CTSB | P07858 | 5/20 | 0.33 |
| ▸ | CTSH | P09668 | 4/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335506 | 0.84 | LTA4H (0.43) | ALDH1A1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL3335513 | 0.84 | LTA4H (0.43) | ALDH1A1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL392983 | 0.83 | KMT2A (0.39) | ALDH1A1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL392982 | 0.83 | KMT2A (0.39) | ALDH1A1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL392112 | 0.72 | ATM (0.46) | ALDH1A1KMT2ACTSKCTSLCTSB | |
| SCHEMBL392111 | 0.72 | ATM (0.46) | ALDH1A1KMT2ACTSKCTSLCTSB | |
| SCHEMBL9205347 | 0.71 | CYP1A2 (0.36) | CTSKCTSLCTSBCTSH | |
| SCHEMBL13155423 | 0.68 | LTA4H (0.47) | ALDH1A1KMT2ALTA4HCTSKCTSL | |
| SCHEMBL24328858 | 0.67 | SLC1A3 (0.40) | LTA4HCTSKCTSLCTSB | |
| SCHEMBL28191857 | 0.67 | SLC1A3 (0.40) | LTA4HCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088787-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120088834-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-8106232-B2 | 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists | THERAVANCE, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8101794-B2 | Crystalline forms of a 3-carboxypropyl-aminotetralin compound | THERAVANCE, INC. (US) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088787-A1 | 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRL1, OPRM1, OPRK1 | ALDH1A1 601/4885KMT2A 2107/4885LTA4H 1258/4885 |
| US-20120088834-A1 | CRYSTALLINE FORMS OF A 3-CARBOXYPROPYL-AMINOTETRALIN COMPOUND | OPRM1, OPRK1, OPRL1 | ALDH1A1 1569/4885KMT2A 2248/4885LTA4H 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.